These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9740952)

  • 1. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
    Crichton AC
    Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
    Chen TC
    J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
    Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
    Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
    Schadlu R; Maus TL; Nau CB; Brubaker RF
    Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
    Williams GC; Orengo-Nania S; Gross RL
    J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
    Sebastiani A; Parmeggiani F; Costagliola C; Ciancaglini M; D'Oronzo E; Mastropasqua L
    Acta Ophthalmol Scand Suppl; 2002; 236():29-30. PubMed ID: 12390124
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
    Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
    J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More than just an ocular solution.
    Pekdemir M; Yanturali S; Karakus G
    Emerg Med J; 2005 Oct; 22(10):753-4. PubMed ID: 16189050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
    Chevrier RL; Assalian A; Duperré J; Lesk MR
    Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alpha-2 adrenergic agonists in the treatment of glaucoma].
    Apătăchioae I; Chiseliţă D
    Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to topical apraclonidine in children with glaucoma.
    Wright TM; Freedman SF
    J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery.
    Dahlmann-Noor AH; Cosgrave E; Lowe S; Bailly M; Vivian AJ
    J AAPOS; 2009 Apr; 13(2):123-6. PubMed ID: 19393510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
    Yuen NS; Cheung P; Hui SP
    Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Gebhardt DO
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):275. PubMed ID: 10086159
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological advances in the treatment of glaucoma.
    Serle JB
    Drugs Aging; 1994 Sep; 5(3):156-70. PubMed ID: 7803944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.